Bradley Herring Sells 4,134 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 4,134 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $41,877.42. Following the sale, the chief financial officer now owns 266,369 shares in the company, valued at approximately $2,698,317.97. The trade was a 1.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Bradley Herring also recently made the following trade(s):

• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23.

Enfusion Stock Down 3.1 %

ENFN stock traded down $0.32 during mid-day trading on Friday, hitting $9.97. The company had a trading volume of 351,403 shares, compared to its average volume of 388,016. The company has a 50-day moving average price of $10.09 and a 200 day moving average price of $9.18. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of 249.31, a P/E/G ratio of 3.98 and a beta of 0.95.

Analyst Ratings Changes

Several brokerages recently weighed in on ENFN. Piper Sandler upped their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus upped their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Enfusion has a consensus rating of “Hold” and a consensus price target of $10.25.

Institutional Investors Weigh In On Enfusion

A number of hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock valued at $9,770,000 after acquiring an additional 70,367 shares during the last quarter. Scalar Gauge Management LLC raised its position in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock valued at $5,227,000 after purchasing an additional 110,000 shares during the period. Wellington Management Group LLP lifted its stake in shares of Enfusion by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after purchasing an additional 61,032 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Enfusion by 167.6% in the 2nd quarter. Renaissance Technologies LLC now owns 97,100 shares of the company’s stock valued at $827,000 after purchasing an additional 60,811 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after purchasing an additional 61,554 shares during the period. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.